← Back to Search

Aprepitant for Opioid-Induced Cognitive Impairment

N/A

Waitlist Available

Led By Kai Schoenhage, MD

Research Sponsored by University of Arizona

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 3 days post-operatively

Awards & highlights

Study Summary

This trial is testing if a new medication can help to reduce some of these common side effects from opioids, without reducing the pain control that the opioids provide.

Who is the study for?

This trial is for healthy, English-speaking adults who have never taken opioids before. It's not for those who are very overweight, have liver issues, infections, recent surgery or bleeding problems. Pregnant or nursing women and people under 18 can't join either.Check my eligibility

What is being tested?

The study is testing if Aprepitant can help with the cognitive side effects of opioids used for pain after surgery. Participants will be randomly given either Aprepitant or a placebo to see which works better.See study design

What are the potential side effects?

Aprepitant may cause headaches, tiredness, hiccups, constipation and other digestive symptoms. However, it's generally considered safe with manageable side effects.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 3 days post-operatively

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~3 days post-operatively

This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 days post-operatively for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

cognitive function

Trial Design

2Treatment groups

Active Control

Placebo Group

Group I: AprepitantActive Control1 Intervention

Aprepitant 40 mg IV pre-operatively 40 mg PO post-op day #1 40 mg PO post-op day #2

Group II: PlaceboPlacebo Group1 Intervention

electrolyte (0.9% NaCl) infusion) pre-operatively capsule without medication on post-op day #1 capsule without medication on post-op day #2

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of ArizonaLead Sponsor

516 Previous Clinical Trials

148,650 Total Patients Enrolled

Kai Schoenhage, MDPrincipal InvestigatorUniversity of Arizona

3 Previous Clinical Trials

370 Total Patients Enrolled

Media Library

Aprepitant Clinical Trial Eligibility Overview. Trial Name: NCT02226601 — N/A

Cognitive Impairment Research Study Groups: Aprepitant, Placebo

Cognitive Impairment Clinical Trial 2023: Aprepitant Highlights & Side Effects. Trial Name: NCT02226601 — N/A

Aprepitant 2023 Treatment Timeline for Medical Study. Trial Name: NCT02226601 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many participants are currently participating in this research study?

"This medical trial is no longer actively recruiting participants. The original posting was on October 1st 2014, and the latest update occured May 29th 2015. For those looking for similar studies, there are presently 569 trials searching for patients with cognitive decline, and 7 studies that involve Aprepitant currently admitting individuals."

Answered by AI

Is recruitment for this research endeavor still active?

"This clinical trial is no longer actively recruiting participants; the last time it was updated on the website was May 29th, 2015. If you are seeking other trials, there are presently 569 studies that accept individuals with cognitive decline and 7 for Aprepitant which continue to admit patients."

Answered by AI

Am I eligible to join this medical research?

"Candidates who wish to participate in this experiment must be cognitively impaired and aged between 18-85. The research team is aiming to recruit 50 people for the study."

Answered by AI

Is this trial available to octogenarians?

"This clinical trial is accessible to patients aged 18-85, with 24 studies for minors and 540 for seniors."

Answered by AI

Is this a pioneering research project?

"Presently, 7 trials involving Aprepitant are being conducted in 3 nations and 4 cities. The original research began in 2009 with Merck Sharp & Dohme LLC as the sponsor. This initial study concluded its drug approval phase and involved 50 patients. Since that time, 18,417 studies have been completed regarding this medication."

Answered by AI

Recent research and studies

Addiction BiologyJournal

Effects of the Nk<sub>1</sub>antagonist, Aprepitant, on Response to Oral and Intranasal Oxycodone in Prescription Opioid Abusers

Walsh, Sharon L., Markus Heilig, Paul A. Nuzzo, Pam Henderson, and Michelle R. Lofwall. 2012. “Effects of the Nk1antagonist, Aprepitant, on Response to Oral and Intranasal Oxycodone in Prescription Opioid Abusers”. Addiction Biology. Wiley. doi:10.1111/j.1369-1600.2011.00419.x.

clinicaltrials.govStudy

Aprepitant to Mitigate Opioids' Cognitive Side Effects

Kai Schoenhage 2014. "Aprepitant to Mitigate Opioids' Cognitive Side Effects". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT02226601.

All > Mci